Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study

Blood (2024) 144 (Supplement 1): 58.

https://doi.org/10.1182/blood-2024-205592

Published: 2024

Journal Articles

Laboratories Can Reliably Detect Clinically Relevant Variants in the TP53 Gene below 10 % Allelic Frequency: A Multicenter Study of ERIC, the European Research Initiative on CLL

Sarka Pavlova, Jitka Malcikova, Lenka Radova, Silvia Bonfiglio, Jack B. Cowland, Christian Brieghel, Mette Klarskov Andersen, Maria Karypidou, Bella V Biderman, Michael Doubek, Gregory Lazarian, Inmaculada Rapado, Matthijs Vynck, Naomi Porret, Martin Andres, Dina Rosenberg, Dvora Sahar, Carolina Martinez-Laperche, Ismael Buño Borde, Andrew Hindley, Julio Bravo Sánchez, José García-Marco, Alicia Serrano, Blanca Ferrer Lores, Concepción Fernández-Rodriguez, Beatriz Bellosillo, Stephan Stilgenbauer, Eugen Tausch, Hero Nikdin, Fiona Quinn, Emer Atkinson, Lisette Van De Corput, Cafer Yildiz, Cristina Bilbao, Yanira Florido, Christian Thiede, Caroline Schuster, Anastazja Stoj, Sylwia Czekalska, Anastasia Chatzidimitriou, Stamatia Laidou, Audrey Bidet, Charles Dussiau, Friedel Nollet, Giovanna Piras, Tereza Borosova, Terezia Kurucova, Maria Monne, Svetlana Smirnova, Evgeny Nikitin, Ivan Sloma, Marie-Helene Delfau, Laetitia Largeaud, Loic Ysebaert, Peter J. M. Valk, Amy Christian, Renata Walewska, Marta Sebastião, Maria Gomes da Silva, Piero Galieni, Mario Angelini, Davide Rossi, Valeria Spina, Sónia Matos, Vânia Martins, David Donaldson, Tomasz Stoklosa, Monika Pepek, Panagiotis Baliakas, Rafa Andreu, Irene Luna, Tiina Kahre, Ülle Murumets, Sophie Laird, Daniel Ward, Miguel Alcoceba, Ana Balanzategui, Lydia Scarfo, Francesca Gandini, Ettore Zapparoli, Adoracion Blanco, Pau Abrisqueta Costa, Ana E. Rodriguez, Maria Rocio Benito Sanchez, Frédéric Davi, Clothilde Bravetti, Paula Gameiro, Joaquin Martinez-Lopez, Barbara Tazon, Fanny Baran-Marszak, Zadie Davies, Mark Caterwood, Andrey B Sudarikov, Richard Rosenquist, Carsten Utoft Niemann, Kostas Stamatopoulos, Paolo Ghia, Sarka Pospisilova

Blood (2023) 142 (Supplement 1): 200.

https://doi.org/10.1182/blood-2023-173235

Published: 2023

Journal Articles

Clonal Dynamics of FLT3 -ITD Positive Acute Myeloid Leukemia Patients with Relapsed/Refractory Disease Following Intensive Chemotherapy +/- Midostaurin

Romane Joudinaud, Augustin Boudry, Laurène Fenwarth, Sandrine Geffroy, Mikaël Salson, Herve Dombret, Céline Berthon, Arnaud Pigneux, Delphine Lebon, Lamya Haddaoui, Raphael Itzykson, Christian Recher, Audrey Bidet, Eric Delabesse, Mathilde Hunault, Claude Preudhomme, Nicolas Duployez, Pierre-Yves Dumas

Blood (2023) 142 (Supplement 1): 976.

https://doi.org/10.1182/blood-2023-182018

Published: 2023

Journal Articles

Molecular Relapse after First-Line Intensive Therapy in Patients with Core-Binding Factor and NPM1 -Mutated Acute Myeloid Leukemia - a Filo Study

Corentin Orvain, Sarah Bertoli, Pierre Peterlin, Yohan Desbrosses, Pierre-Yves Dumas, Alexandre Iat, Marie Anne Hospital, Martin Carre, Emmanuelle Tavernier, Anne Bouvier, Audrey Bidet, Sylvie Tondeur, Florian Renosi, Eric Delabesse, Arnaud Pigneux, Hunault-Berger Mathilde, Christian Recher

Blood (2023) 142 (Supplement 1): 421.

https://doi.org/10.1182/blood-2023-184848

Published: 2023

Journal Articles

Association between Molecular Profile and Outcome after Intensive Chemotherapy in Patients > 60 Years with Adverse Cytogenetic Risk and/or Secondary Acute Myeloid Leukemia - a Filo Study

Corentin Orvain, Anne Bouvier, Audrey Bidet, Pierre-Yves Dumas, Sarah Bertoli, Odile Blanchet, Sylvain Thepot, Aline Schmidt, Arnaud Pigneux, Eric Delabesse, Christian Recher, Hunault-Berger Mathilde

Blood (2023) 142 (Supplement 1): 2851.

https://doi.org/10.1182/blood-2023-184815

Published: 2023

Journal Articles

Venetoclax and Azacitidine for Molecular Relapse during First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Study from the Dataml Registry

Jules Higué, Pierre-Yves Dumas, Laetitia Largeaud, Audrey Bidet, Émilie Klein, Olivier Mansier, Lucie Rigolot, Eric Delabesse, Anne Banos, Suzanne Tavitian, Thibaut Leguay, Sarah Guenounou, Edouard Forcade, Sarah Bertoli, Arnaud Pigneux, Christian Recher

Blood (2023) 142 (Supplement 1): 2887.

https://doi.org/10.1182/blood-2023-180773

Published: 2023

Journal Articles

Tyrosine Kinase Inhibitors with Intensive Chemotherapy in AML with t(9;22)(q34.1;q11.2)/ BCR::ABL1 : Time to Reconsider Prognostic Risk? a Study from the Dataml Registry

Camille Gondran, Pierre-Yves Dumas, Audrey Bidet, Emilie Bérard, Suzanne Tavitian, Thibaut Leguay, Françoise Huguet, Isabelle Luquet, Émilie Klein, Audrey Sarry, Anne-Charlotte De Grande, Eric Delabesse, Édouard Forcade, Cécile Borel, Arnaud Pigneux, Christian Recher, Laetitia Largeaud, Sarah Bertoli

Blood (2023) 142 (Supplement 1): 1473.

https://doi.org/10.1182/blood-2023-180817

Published: 2023

Journal Articles

Levofloxacin to Prevent Bacterial Infection in Patients with Acute Myeloid Leukemia Treated By Azacitidine and Venetoclax: A Study from the Dataml Registry

Blood (2023) 142 (Supplement 1): 7443.

https://doi.org/10.1182/blood-2023-182117

Published: 2023

Journal Articles

Overlapping features of therapy-related and de novo NPM1 -mutated AML

Blood (2023) 141 (15): 1846–1857.

https://doi.org/10.1182/blood.2022018108

Published: 2023

Includes: Supplemental data

Journal Articles

Epag 2015 : A Phase II Randomized Placebo-Controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy. a French Innovative Leukemia Organization (FILO) Study

Blood (2022) 140 (Supplement 1): 6142–6144.

https://doi.org/10.1182/blood-2022-167000

Published: 2022

Journal Articles

Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study

Blood (2022) 140 (7): 756–768.

https://doi.org/10.1182/blood.2021015328

Published: 2022

Includes: Supplemental data

Journal Articles

Long-Term Survival after Intensive Chemotherapy or Hypomethylating Agents in AML Patients Aged 70 Years and Older: A Large Patient Data Set Study from Dataml, SAL and Pethema European Registries

Blood (2021) 138 (Supplement 1): 872.

https://doi.org/10.1182/blood-2021-147735

Published: 2021

Journal Articles

Artificial Intelligence-Based Predictive Models for Acute Myeloid Leukemia

Ibrahim Didi, David Simoncini, Francois Vergez, Pierre-Yves Dumas, Suzanne Tavitian, Laetitia Largeaud, Audrey Bidet, Jean-Baptiste Rieu, Isabelle Luquet, Nicolas Lechevalier, Eric Delabesse, Audrey Sarry, Anne-Charlotte De Grande, Emilie Berard, Arnaud Pigneux, Christian Recher, Jean-Marc Alliot, Sarah Bertoli

Blood (2021) 138 (Supplement 1): 3389.

https://doi.org/10.1182/blood-2021-145122

Published: 2021

Journal Articles

Prognostic Significance of DDX41 Germline Mutations in Intensively Treated AML Patients: An ALFA-Filo Study

Nicolas Duployez, Matthieu Duchmann, Laetitia Largeaud, Juliette Lambert, Audrey Bidet, Emmanuelle Clappier, Xavier Thomas, Stephane de Botton, Claude Gardin, Christian Recher, Arnaud Pigneux, Raphael Itzykson, Claude Preudhomme, Hervé Dombret, Eric Delabesse, Marie Sebert

Blood (2021) 138 (Supplement 1): 612.

https://doi.org/10.1182/blood-2021-148465

Published: 2021

Journal Articles

Unsupervised Flow Cytometry Analysis: Application to Minimal Residual Disease Detection in a Cohort of 40 Acute Myeloblastic Leukemia Patients with Molecular Markers

Nicolas Lechevalier, PharmD, Jean-Philippe Vial, MD, Francis Lacombe, MDPhD, Pierre-Yves Dumas, MDPhD, Audrey Bidet, PharmD, Thibaut Leguay, MD, Francois Vergez, DVM, PhD, Arnaud Pigneux, MD PhD, Marie C Béné, PharmSciD, PhD

Blood (2020) 136 (Supplement 1): 30.

https://doi.org/10.1182/blood-2020-141199

Published: 2020

Journal Articles

MYC and KMT2A multiple extra copies in acute myeloid leukemia

Emilie Klein, Audrey Bidet

Blood (2020) 135 (13): 1070.

https://doi.org/10.1182/blood.2019004551

Published: 2020

Journal Articles

The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants

Blood (2019) 134 (Supplement_1): 3021.

https://doi.org/10.1182/blood-2019-130907

Published: 2019

Journal Articles

Improved Outcome with a Pediatric-Inspired Regimen for Philadelphia-Negative Acute Lymphoblastic Leukemia in the Elderly

Francois Xavier Gros, MD, Pierre-Yves Dumas, MD, Edouard Forcade, MD, Claire Calmettes, MD, Margot Robles, MD, Vincent Servant, PharmD, Nicolas Lechevalier, PharmD, Audrey Bidet, PharmD, Noel Milpied, Arnaud Pigneux, MD PhD, Thibaut Leguay, MD

Blood (2017) 130 (Supplement 1): 2560.

https://doi.org/10.1182/blood.V130.Suppl_1.2560.2560

Published: 2017

Journal Articles

A Retrospective Analysis of 450 TP53 Mutations in a Real Life Cohort of CLL from the French Innovative Leukemia Organization (FILO) Group

Blood (2017) 130 (Supplement 1): 1722.

https://doi.org/10.1182/blood.V130.Suppl_1.1722.1722

Published: 2017

Journal Articles

Feasibility and Outcome of Late Intensification with Native L-Asparaginase for Acute Lymphoblastic Leukemia in the Elderly: A Single Center Experience

Blood (2017) 130 (Supplement 1): 1296.

https://doi.org/10.1182/blood.V130.Suppl_1.1296.1296

Published: 2017

NARROW

Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study

Laboratories Can Reliably Detect Clinically Relevant Variants in the TP53 Gene below 10 % Allelic Frequency: A Multicenter Study of ERIC, the European Research Initiative on CLL

Clonal Dynamics of FLT3 -ITD Positive Acute Myeloid Leukemia Patients with Relapsed/Refractory Disease Following Intensive Chemotherapy +/- Midostaurin

Molecular Relapse after First-Line Intensive Therapy in Patients with Core-Binding Factor and NPM1 -Mutated Acute Myeloid Leukemia - a Filo Study

Association between Molecular Profile and Outcome after Intensive Chemotherapy in Patients > 60 Years with Adverse Cytogenetic Risk and/or Secondary Acute Myeloid Leukemia - a Filo Study

Venetoclax and Azacitidine for Molecular Relapse during First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Study from the Dataml Registry

Tyrosine Kinase Inhibitors with Intensive Chemotherapy in AML with t(9;22)(q34.1;q11.2)/ BCR::ABL1 : Time to Reconsider Prognostic Risk? a Study from the Dataml Registry

Levofloxacin to Prevent Bacterial Infection in Patients with Acute Myeloid Leukemia Treated By Azacitidine and Venetoclax: A Study from the Dataml Registry

Overlapping features of therapy-related and de novo NPM1 -mutated AML

Epag 2015 : A Phase II Randomized Placebo-Controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy. a French Innovative Leukemia Organization (FILO) Study

Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study

Long-Term Survival after Intensive Chemotherapy or Hypomethylating Agents in AML Patients Aged 70 Years and Older: A Large Patient Data Set Study from Dataml, SAL and Pethema European Registries

Artificial Intelligence-Based Predictive Models for Acute Myeloid Leukemia

Prognostic Significance of DDX41 Germline Mutations in Intensively Treated AML Patients: An ALFA-Filo Study

Unsupervised Flow Cytometry Analysis: Application to Minimal Residual Disease Detection in a Cohort of 40 Acute Myeloblastic Leukemia Patients with Molecular Markers

MYC and KMT2A multiple extra copies in acute myeloid leukemia

The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants

Improved Outcome with a Pediatric-Inspired Regimen for Philadelphia-Negative Acute Lymphoblastic Leukemia in the Elderly

A Retrospective Analysis of 450 TP53 Mutations in a Real Life Cohort of CLL from the French Innovative Leukemia Organization (FILO) Group

Feasibility and Outcome of Late Intensification with Native L-Asparaginase for Acute Lymphoblastic Leukemia in the Elderly: A Single Center Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only